Abnormal effect of hydroxyl on the longest wavelength maximum in ultraviolet absorption spectra for bis-aryl Schiff bases
作者:Chao-Tun Cao、Wei Zhou、Chenzhong Cao
DOI:10.1002/poc.3672
日期:2017.10
4‐HOArCH=NArY and XArCH=NArOH‐4′, and the second set consists of 2‐HOArCH=NArY and XArCH=NArOH‐2′. Their ultravioletabsorptionspectra were measured and investigated. A very interesting phenomenon was observed by analyzing their wave number νmax (cm−1) of longest wavelength maximum λmax (nm) of ultraviolet. Compared with the change regularity of the νmax of XArCH=NArY (where the X and Y excluded OH), the
Anion Effect on the Formation of Zinc‐Salicyaldimine Compounds in Neutral and Anionic Complex Forms: Synthesis, Characterization,
<sup>1</sup>
H NMR Studies, and Photophysical Properties
作者:Meng‐Jung Tsai、Yo‐Ting Su、Jing‐Yun Wu
DOI:10.1002/ejic.202100377
日期:2021.8.20
different zinc-binding abilities. 1HNMRstudies indicate different degrees of decomplexation of 2 in different solvents, leading to a dynamic equilibrium between the zinc-salicyaldimine complex form and the neutral form of salicyaldimine ligand. This is achieved by proton transfer and interpreted by the hydrogen-bonding properties of the solvents. Photophysical studies reveal that Hsal-3-PhCN exhibited
Effect of substituents on the UV spectra of supermolecular system: Silver nanoparticles with bi-aryl Schiff bases containing hydroxyl
作者:Chao-Tun Cao、Shimao Cheng、Jingyuan Zhang、Chenzhong Cao
DOI:10.1002/poc.3910
日期:2019.3
Effect of substituents on the ultraviolet (UV) spectra of supermolecular system involving silver nanoparticles (AgNPs) and Schiffbases was investigated. AgNPs and 49 samples of model compounds (MC), bi‐aryl Schiffbases containing hydroxyl (XBAY, involving 4‐OHArCHNArY, 2‐OHArCHNArY, XArCHNAr‐4′‐OH, and XArCHNAr‐2′‐OH), were synthesized. The size of AgNPs was characterized by transmission electron
Novel quinone-fused oxazepines compounds that inhibit peroxiredoxins, pharmaceutical compositions comprising such compounds, are disclosed. Additionally, methods of treating or alleviating conditions associated with elevated peroxiredoxins levels, and in particular cancer, are also disclosed.